GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                                     
                            
                            
                            
                                 Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: NSC61610 is a LANCL2 modulator that was discovered using high-throughput, structure-based virtual screening [2]. It has a poor drug-like profile, passing only one of the six Lipinski-like filters. Omilancor was designed as an improved version of NSC61610 (it passes three of the Lipinski rules).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J. (2016)
                                         An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. J Med Chem, 59 (22): 10113-10126. [PMID:27933891]  | 
                                                                
| 
                                                                         2. Lu P, Hontecillas R, Horne WT, Carbo A, Viladomiu M, Pedragosa M, Bevan DR, Lewis SN, Bassaganya-Riera J. (2012)
                                         Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2. PLoS ONE, 7 (4): e34643. [PMID:22509338]  |